已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

New biomarkers in acute kidney injury

急性肾损伤 少尿 医学 重症监护医学 肾脏疾病 无尿 肌酐 人口 内科学 肾功能 环境卫生
作者
Adam Rossiter,Ashley La,Jay L. Koyner,Lui G. Forni
出处
期刊:Critical Reviews in Clinical Laboratory Sciences [Taylor & Francis]
卷期号:61 (1): 23-44 被引量:18
标识
DOI:10.1080/10408363.2023.2242481
摘要

AbstractAcute kidney injury (AKI) is a commonly encountered clinical syndrome. Although it often complicates community acquired illness, it is more common in hospitalized patients, particularly those who are critically ill or who have undergone major surgery. Approximately 20% of hospitalized adult patients develop an AKI during their hospital care, and this rises to nearly 60% in the critically ill, depending on the population being considered. In general, AKI is more common in older adults, in those with preexisting chronic kidney disease and in those with known risk factors for AKI (including diabetes and hypertension). The development of AKI is associated with an increase in both mortality and morbidity, including the development of post-AKI chronic kidney disease. Currently, AKI is defined by a rise in serum creatinine from either a known or derived baseline value and/or oliguria or anuria. However, clinicians may fail to recognize the initial development of AKI because of a delay in the rise of serum creatinine or because of inaccurate urine output monitoring. This, in turn, delays any putative measures to treat AKI or to limit its degree. Consequently, efforts have focused on new biomarkers associated with AKI that may allow early recognition of this syndrome with the intent that this will translate into improved patient outcomes. Here we outline current biomarkers associated with AKI and explore their potential in aiding diagnosis, understanding the pathophysiology and directing therapy.Keywords: Acute kidney injuryacute kidney diseasechronic kidney diseasebiomarkers Disclosure statementJ.L.K has received consulting fees from Astute-Biomerieux, Sphingotec, Pfizer, Baxter, Mallinckrodt, Novartis, Guard Therapeutics, research funding from Astute-Biomerieux Medical, Bioporto, NxStage, Fresenius, Satellite Healthcare, and speaker fees from NxStage medical; L.G.F has received research support and lecture fees from Ortho Clinical Diagnostics, Baxter, Exthera and Biomerieux and consulting fees from La Jolla Pharmaceuticals and Paion. A.R. and A.L. declare no competing interests.Funding statementThe authors reported that there is no funding associated with the work featured in this article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
czy完成签到 ,获得积分10
刚刚
1秒前
ZTLlele完成签到 ,获得积分10
1秒前
duohao2023发布了新的文献求助30
3秒前
Zhang完成签到 ,获得积分10
5秒前
Benjamin完成签到 ,获得积分10
6秒前
yx_cheng应助蓝天白云采纳,获得10
6秒前
max发布了新的文献求助10
7秒前
9秒前
struggling2026完成签到 ,获得积分10
10秒前
breeze完成签到,获得积分10
15秒前
15秒前
优雅夕阳完成签到 ,获得积分10
16秒前
奋斗的小笼包完成签到 ,获得积分10
19秒前
儿学化学打断腿完成签到,获得积分10
20秒前
20秒前
23秒前
hh完成签到 ,获得积分10
27秒前
元宝团子完成签到,获得积分10
30秒前
Bearbiscuit完成签到,获得积分10
30秒前
30秒前
张元东完成签到 ,获得积分10
34秒前
35秒前
36秒前
36秒前
38秒前
39秒前
anthea完成签到 ,获得积分10
39秒前
一直向前发布了新的文献求助10
40秒前
含糊的尔槐完成签到,获得积分10
41秒前
lizigongzhu发布了新的文献求助10
43秒前
43秒前
苏和杨发布了新的文献求助10
44秒前
44秒前
46秒前
47秒前
CodeCraft应助科研通管家采纳,获得10
48秒前
JamesPei应助科研通管家采纳,获得10
48秒前
完美世界应助科研通管家采纳,获得10
48秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989957
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256000
捐赠科研通 3270880
什么是DOI,文献DOI怎么找? 1805070
邀请新用户注册赠送积分活动 882252
科研通“疑难数据库(出版商)”最低求助积分说明 809216